LB54640
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| DrugBank | |
LB54640 is a small molecule melanocortin 4 receptor agonist developed by LG Chem Life Sciences for hypothalamic obesity. Unlike the older drug with the same mechanism of action, setmelanotide, it can be taken by mouth.[1][2][3]
References
[edit]- ^ Aronne, Sarah R. Barenbaum, Louis J. (2023). "Antiobesity Medications on the Horizon". Handbook of Obesity - Volume 2 (5 ed.). CRC Press. pp. 394–401. doi:10.1201/9781003432807-42. ISBN 978-1-003-43280-7.
{{cite book}}: CS1 maint: multiple names: authors list (link) - ^ First-in-Human Study of Safety, Pharmacodynamics of LB54640, An Oral Melanocortin-4 Receptor Agonist Mirza, Victoria, MD, MPH; Lee, Jisoo, MD; Gwak, Heemin; Yang, Yunjeong; Kim, Mina. Obesity; Silver Spring Vol. 30, (Nov 2022): 145-146.
- ^ Piper, Noah B.C.; Whitfield, Emily A.; Stewart, Gregory D.; Xu, Xiaomeng; Furness, Sebastian G.B. (August 2022). "Targeting appetite and satiety in diabetes and obesity, via G protein-coupled receptors". Biochemical Pharmacology. 202: 115115. doi:10.1016/j.bcp.2022.115115. PMID 35671790. S2CID 249452717.